ZURA — Zura Bio Limited - Class A Ordinary shares
Session close: $1.24. Regular-session share volume: 53,769,505. Change from previous close: -69.68%.
Key developments
Coverage of the session was largely limited to price-mover roundups, which attributed the sharp decline to the trial failing its primary and secondary endpoints. Broader market and sector context showed U.S. equities trading higher, indicating the move was company-specific rather than driven by the wider market.
Market context — Mentions ZURA in the article text. 12 Health Care Stocks Moving In Monday's Intraday Session · Market context — Mentions ZURA in the article text. 12 Health Care Stocks Moving In Monday's Pre-Market Session · Company mentioned — Mentions ZURA in the article text. Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results · Company mentioned — Mentions ZURA in the article text. Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings
News sources
Company news Wedbush Maintains Outperform on Zura Bio, Lowers Price Target to $10 · Company news Zura Bio Phase 2 Trial of Tibulizumab in Hidradenitis Suppurativa Fails to Meet Primary Endpoint · Company news Zura Bio Says Phase 2 TibuSHIELD Study Of Tibulizumab In Hidradenitis Suppurativa Missed Primary And Key Secondary Endpoints · Company news Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa · Market context — Mentions ZURA in the article text. 12 Health Care Stocks Moving In Monday's Intraday Session · Market context — Mentions ZURA in the article text. 12 Health Care Stocks Moving In Monday's Pre-Market Session · Company mentioned — Mentions ZURA in the article text. Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results · Company mentioned — Mentions ZURA in the article text. Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings